Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia.

Aged Biomarkers / analysis Disease Progression Female Follow-Up Studies Genotype Hemoglobins / analysis Humans Male Middle Aged Multivariate Analysis Mutation Myeloid Differentiation Factor 88 / genetics Predictive Value of Tests Receptors, CXCR4 / genetics Retrospective Studies Risk Factors Survival Waldenstrom Macroglobulinemia / blood beta 2-Microglobulin / blood

CXCR4 IgM monoclonal gammopathy MYD88 asymptomatic lymphoplasmacytic lymphoma

Journal

British journal of haematology

ISSN: 1365-2141

Titre abrégé: Br J Haematol

Pays: England

ID NLM: 0372544

Informations de publication

Date de publication:
10 2021

Historique:

revised: 26 05 2021

received: 16 03 2021

accepted: 03 06 2021

pubmed: 3 8 2021

medline: 17 12 2021

entrez: 2 8 2021

Statut: ppublish

Résumé

Patients with asymptomatic/smouldering Waldenström macroglobulinaemia (SWM) have a variable risk of progression to active WM. Our study evaluated 143 patients with SWM consecutively seen between January 1996 and December 2013. With a median [95% confidence interval (CI)] follow-up of 9·5 [8·1-11·5] years, the cumulative rate of progression was 11% at 1 year, 38% at 3 years and 55% at 5 years. On multivariate analysis, haemoglobin (Hb) ≤123 g/l [risk ratio (RR) 2·08; P = 0·009] and β

Identifiants

DOI: 10.1111/bjh.17691 PMID: 34340248

pubmed: 34340248

doi: 10.1111/bjh.17691

doi:

Substances chimiques

Biomarkers 0

CXCR4 protein, human 0

Hemoglobins 0

Myeloid Differentiation Factor 88 0

Receptors, CXCR4 0

beta 2-Microglobulin 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

210-216

Commentaires et corrections

Type : CommentIn

Informations de copyright

Références

Kapoor P, Ansell SM, Fonseca R, Chanan-Khan A, Kyle RA, Kumar SK, et al. Diagnosis and management of Waldenstrom macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines 2016. JAMA Oncol. 2017, 3, 1257-65.

Kyle RA, Therneau TM, Rajkumar SV, Remstein ED, Offord JR, Larson DR, et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood. 2003;102:3759-64.

Paiva B, Corchete LA, Vidriales MB, Garcia-Sanz R, Perez JJ, Aires-Mejia I, et al. The cellular origin and malignant transformation of Waldenstrom macroglobulinemia. Blood. 2015;125:2370-80.

Braggio E, Keats JJ, Leleu X, Van Wier S, Jimenez-Zepeda VH, Valdez R, et al. Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia. Cancer Res. 2009;69:3579-88.

Nguyen-Khac F, Lambert J, Chapiro E, Grelier A, Mould S, Barin C, et al. Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia. Haematologica. 2013;98:649-54.

Stone MJ, Merlini G, Pascual V. Autoantibody activity in Waldenström's macroglobulinemia. Clin Lymphoma. 2005;5:225-9.

Abeykoon JP, Zanwar S, Ansell SM, Winters J, Gertz MA, King RL, et al. Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia. Am. J. Hematol. 2018;93:1384-93.

Dimopoulos MA, Kastritis E, Ghobrial IM. Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics. Ann Oncol. 2016;27:233-40.

Kyle RA, Treon SP, Alexanian R, Barlogie B, Björkholm M, Dhodapkar M, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin. Oncol. 2003;30:116-20.

Treon SP. How I treat Waldenström macroglobulinemia. Blood. 2015;126:721-32.

Stone MJ. Waldenstrom's macroglobulinemia: hyperviscosity syndrome and cryoglobulinemia. Clin Lymphoma Myeloma. 2009;9:97-9.

Zanwar S, Abeykoon JP, Ansell SM, Gertz MA, Dispenzieri A, Muchtar E, et al. Primary systemic amyloidosis in patients with Waldenstrom macroglobulinemia. Leukemia. 2019;33:790-4.

Kyle RA, Benson JT, Larson DR, Therneau TM, Dispenzieri A, Kumar S, et al. Progression in smoldering Waldenstrom macroglobulinemia: long-term results. Blood. 2012;119:4462-6.

Alexanian R, Weber D, Delasalle K, Cabanillas F, Dimopoulos M. Asymptomatic Waldenstrom's macroglobulinemia. Semin. Oncol. 2003;30:206-10.

Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. International Agency for Research on Cancer; 2017.

Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695-706.

Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538-48.

Bustoros M, Sklavenitis-Pistofidis R, Kapoor P, Liu CJ, Kastritis E, Zanwar S, et al. Progression risk stratification of asymptomatic Waldenström macroglobulinemia. J Clin Oncol. 2019;37:1403-11.

Zanwar S, Abeykoon JP, Durot E, King R, Perez Burbano GE, Kumar S, et al. Impact of MYD88(L265P) mutation status on histological transformation of Waldenström macroglobulinemia. Am J Hematol. 2020;95:274-81.

Hunter ZR, Xu L, Tsakmaklis N, Demos MG, Kofides A, Jimenez C, et al. Insights into the genomic landscape of MYD88 wild-type Waldenstrom macroglobulinemia. Blood Adv. 2018;2:2937-46.

Varettoni M, Zibellini S, Defrancesco I, Ferretti VV, Rizzo E, Malcovati L, et al. Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. Haematologica. 2017;102:2077-85.

Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, et al. MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia. N Engl J Med. 2012;367:826-33.

Hunter ZR, Xu L, Yang G, Zhou Y, Liu X, Cao Y, et al. The genomic landscape of Waldenström macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood. 2014;123:1637-46.